Technology

Curiox vs. Waters Lawsuit Officially Filed... Three Key Issues in the Lawsuit as Seen in the Webinar

Kim Seung-kwon
2026-11-23 07:01:02
[Edaily Reporter Kim Seung-kwon ] Just two days after Curiox Biosystems Co., Ltd.(445680)(hereinafter “Curiox”) filed a trade secret infringement lawsuit in the U.S., the defendant, Waters, disclosed the cleaning mechanism of the equipment in question—the “BD FACS360”—during a webinar.

The disclosed method is understood to be based on the same principle as the technology Curiox described in its complaint. However, the specific operating conditions that Curiox identified as trade secrets were not disclosed. Analysts say this makes it even clearer that the decisive factor in the lawsuit lies not in proving the “principle” but in proving the “parameters.” Pharm E-Daily analyzed the key issues of the lawsuit based on this announcement.

According to industry sources on the 18th, Waters introduced the operating mechanism and performance data of the FACS360 during an online webinar held on the 13th (local time) and sponsored by BD Biosciences. Previously, on the 11th (local time), Curiox filed a complaint in the U.S. District Court for the Northern District of California against BD and Waters, citing five causes of action, including trade secret infringement and breach of a confidentiality agreement (CDA). In addition to seeking damages, Curiox requested an injunction prohibiting the development and sale of the FACS360 to the extent that trade secrets were used, as well as a jury trial.

BD webinar presentation (Source: Screenshot from Waters webinar)

Disclosed washing principle aligns with complaint… Key issue is ‘scope of trade secrets’

According to the webinar presentation materials, FACS360 mixes cells and antibodies in a 96-well round-bottom plate and allows the cells to settle to the bottom by gravity while staining for 30 minutes. It then removes unbound antibodies and debris by repeatedly and carefully aspirating and re-dispensing the wash solution to avoid disturbing the cells.

This overlaps with Curiox’s description in the complaint. Curiox stated in the complaint that its technology, which replaces centrifugation, operates by “sequentially aspirating and dispensing liquid without disturbing the cells that have settled by gravity.” This suggests that official documents confirm both devices share the same fundamental principle.

However, legally speaking, this does not appear to directly constitute proof of infringement. Curiox itself excluded from its trade secrets the publicly disclosed descriptions of centrifuge-free washing in the small intestine and the general principles of pipetting. Instead, it designated five specific categories of operating conditions as trade secrets, including pipette tip height based on liquid volume within the well, aspiration and dispensing speeds, and definitions of 54 liquid classes. These figures were not included in the webinar materials. It is widely expected that Waters will counter with the argument that “aspiration following gravitational sedimentation is a standard industry practice.”

In U.S. trade secret litigation, a key issue is whether the secret claimed by the plaintiff is specific enough to be distinguished from common knowledge. In fact, in a lawsuit filed by the aviation startup Juno Aero against Boeing, a trial judge overturned the jury’s verdict, citing vague descriptions of the trade secret; however, the Ninth Circuit Court of Appeals reinstated the verdict in August of last year. The Ninth Circuit Court of Appeals is also the court with jurisdiction over the appeal in this case.

There is also a noteworthy caveat. Waters included a disclaimer in its cell recovery rate data stating, “Recovery rates may vary depending on the volume of the panel cocktail.” The first trade secret claimed by Curiox involves setting the height of the pipette tip based on the liquid volume in the well. This is interpreted as being related to the fact that Waters’ materials also demonstrated that operating conditions based on liquid volume affect performance. It appears this could become a point of contention during the discovery phase as the two sides compare their respective parameters.

Curiox Biosystems Co., Ltd. stated, “As the lawsuit is currently ongoing, we will not provide any further comment at this time.” A public version of the complaint is available on the Curiox website.

Curiox Biosystems Co., Ltd.’s Pluto product (Photo: Curiox Biosystems Co., Ltd.)


A demonstration attendee as the presenter of a new product… “Approach and timing” are key

The identity of the webinar presenter is also a point of contention. Ali Rezvan, a senior scientist at Waters Biosciences who delivered the presentation, is named in Curiox’s complaint. According to the complaint, he attended a Curiox equipment demonstration held at a BD facility for approximately one week in July 2025.

Curiox cited the fact that he has been introduced as one of the key scientists responsible for developing the FACS360 at Waters as evidence supporting the inference that its technology served as a shortcut in the development process. The speaker introduction in the webinar presentation materials lists “evaluation of new equipment” as one of his areas of expertise.

It is also important to keep an eye on the timeline presented by the director. Curiox claimed that BD retained the equipment for an additional three weeks following the demonstration and that BD received a prototype of the Workflow Wizard and related documentation between August and September of the same year. Furthermore, the company argued that FACS360 was developed just a few months after the disclosure of confidential information, whereas it took them several years to complete the same development. However, a significant portion of these infringement claims takes the form of inferences “based on information and belief.” Since the specific provisions of the CDA are confidential, whether these claims can actually be proven will likely be determined through discovery.

The launch schedule is cited as another variable. During the webinar, the 21 CFR Part 11 (electronic record regulations) compliance feature—which had been listed as “planned for inclusion” on the product introduction page—was changed to “supported,” signaling that the launch is imminent. According to the complaint, Waters plans to begin sales in the U.S. as early as next month.

To block sales prior to launch, a separate motion for a preliminary injunction and a court ruling would be required. Since it is rare for a trade secret lawsuit to halt the launch of a competitor’s product outright, analysts believe the case will likely focus on seeking damages through the main lawsuit.

Meanwhile, during the webinar, Waters emphasized that FACS360 reduced manual labor time from 110 minutes to 23 minutes—a 79% reduction. However, the total process time, including equipment operation, was 253 minutes—63 minutes longer than the 190 minutes required for manual processing. The presentation materials made no mention of the lawsuit.

Economy

Corporation

IT·Science

Economy

"Just How Risky Is the Stock Market on Monday?"…Even the Government Is Taking Emergency Measures

In response to the stock market shock originating in the U.S., the government has begun preparations to activate the Securities Market Stabilization Fund. It is also temporarily relaxing the limits on…
2026-11-23 04:50:04

Corporation

"Beyond the Domestic Home Shopping Market to Vietnam": GS Retail Sees Success in Export Consultations with Small and Medium-Sized Enterprises

GS Retail(007070)has supported domestic small and medium-sized partner companies in Vietnam in expanding their overseas sales channels, resulting in export consultation deals totaling approximately $1…
2026-11-22 18:23:06

IT·Science

Curiox vs. Waters Lawsuit Officially Filed... Three Key Issues in the Lawsuit as Seen in the Webinar

Just two days after Curiox Biosystems Co., Ltd.(445680)(hereinafter “Curiox”) filed a trade secret infringement lawsuit in the U.S., the defendant, Waters, disclosed the cleaning mechanism of the equi…
2026-11-23 07:01:02